Intellijoint Surgical

January 12, 2016

Intellijoint Surgical Wins 2015 Frost & Sullivan Award for Enabling Technology Leadership

Frost & Sullivan Commends Intellijoint Surgical for the Success of intellijoint HIP™

Intellijoint Surgical’s core technology represents the latest in miniature 3D surgical measurement within the sterile field — intellijoint HIP can improve accuracy in achieving preoperative planned targets, ultimately improving patient satisfaction and healthcare economics

MOUNTAIN VIEW, Calif., Jan. 12, 2016 /PRNewswire/ — Based on its recent analysis of the hip replacement market, Frost & Sullivan recognizes Intellijoint Surgical with the 2015 North American Frost & Sullivan Award for Enabling Technology Leadership. Intellijoint Surgical’s flagship product, intellijoint HIP™, can greatly increase the success rates of hip replacement procedures by providing orthopedic surgeons with real-time data measurements of cup position, leg length, and offset intraoperatively. Accurate implant selection and alignment improves patients’ outcomes and reduces overall treatment costs.

“intellijoint HIP™, incorporates Intellijoint Surgical’s proprietary core technology, a miniaturized 3D surgical measurement system placed within the sterile field that provides surgeons with accurate measurements in real-time,” said Frost & Sullivan Best Practices Director,Tonya Fowler. “The data assists surgeons in selecting the best-fitting implant for the patient and helps align the implant in the desired location that is critical for a successful surgical outcome.”

Orthopedic surgeons are equipped with preoperative images of the patient’s hip, but these images are only useful in helping the surgeon create a preoperative plan, not execute it. intellijoint HIP™ provides surgeons with 3D information intraoperatively, helping them with proper implant selection, positioning, and alignment that ultimately improves accuracy in achieving preoperative targets.

Aided by intellijoint HIP™, orthopedic surgeons no longer have to ‘eye ball’ or manually position hip implants, as the device enhances placement precision and minimizes the risk of joint instability, which can lead to additional negative consequences for the patient such as dislocation and leg length discrepancy. intellijoint HIP is safe, fast, accurate and seamlessly integrates with surgeons’ workflows. It is affordable and does not impact operating room time. Additionally, intellijoint HIP™ gives surgeons greater confidence to recommend hip replacement surgery, as the risk for revision hip surgery may be lowered.

Intellijoint Surgical is aware of the huge capital expenses hospitals incur in surgical procedures and, as such, the company does not demand a large upfront capital investment for intellijoint HIP™. Intellijoint Surgical has a pay-per-use model, with manageable fees that do not require C-level executive approvals. The approvals can be obtained from the Operating Room Manager.

“Intellijoint Surgical has demonstrated the long-term viability and impact of its core technology through its innovative new product in hip replacement. It is a great pleasure to recognize Intellijoint Surgical for developing a technology that allows all orthopedic surgeons to benefit from computer-assisted surgery and deliver improved outcomes for their patients,” said Krishna Srinivasan, global president and managing partner, Frost & Sullivan.

For its utility in enhancing the efficiency of orthopedic surgeries and reducing hospital costs, Frost & Sullivan is pleased to present Intellijoint Surgical with the 2015 North American Frost & Sullivan Award for Enabling Technology Leadership.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of newer products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Intellijoint Surgical

Intellijoint Surgical is a Waterloo-based innovative medical technology company. Founded in 2010, they develop and commercialize miniaturized surgical smart tools that enhance surgeon accuracy, increase hospital economic efficiencies, and improve patient outcomes. The company’s R&D team is led by the former co-founder of Medtronic’s computer assisted surgery division, and driven by a team of renowned orthopedic surgeons: Drs. Allan Gross and David Backstein in Toronto, Dr. Wayne Paprosky in Chicago, Dr. Javad Parvizi in Philadelphia and Drs. Michael Cross and Ran Schwarzkopf in New York.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

January 8, 2016

Intellijoint Surgical Receives FDA Clearance for the Next Generation of intellijoint HIP™

A Miniature Surgical Smart Tool for Cup Position, Leg Length, and Offset in Hip Replacement Surgery

WATERLOO, ON–(Marketwired – January 07, 2016) – Intellijoint Surgical Inc., a privately held Canadian medical technology company committed to developing and commercializing miniature surgical smart tools, announces today that it has been awarded US Food and Drug Administration clearance for the next generation of intellijioint HIP™. Cup position (inclination and anteversion) is now provided, in addition to the original leg length, offset, and change in hip center measurements.

“With the previous generation of the product, our use showed improved accuracy and precision of implant selection without a significant expense or impact on OR time,” said Dr. Wayne Paprosky, professor and widely published orthopaedic surgeon at Rush Medical Center in Chicago. “The new generation of intellijoint HIP provides surgeons with additional critical implant alignment measurements including cup inclination and anteversion, which will be a potential game changer of how hip surgery is performed in the US.”

intellijoint HIP can assist in the prevention of recurrent instability, hip dislocation and leg length discrepancy and may expedite decision-making and improve accuracy in achieving preoperative planned targets, ultimately improving patient satisfaction and healthcare economics.

“Intellijoint was founded in 2010 with the vision of developing and commercializing an innovative technology that is capable of providing real time 3D surgical measurement data, without adding significant time, expense or complexity to surgery,” says Armen Bakirtzian, Chief Executive Officer and Co-founder of Intellijoint Surgical. “Now, with FDA clearance ofintellijoint HIP, we’ve realized this vision and are ready to bring its benefits to the largest market in the world.”

Intellijoint’s core technology represents the latest in miniature 3D surgical measurement within the sterile field. intellijoint HIP is the first of many products to benefit from this new novel core technology. It is safe, fast, accurate, and precise. intellijoint HIP‘s compatibility with the majority of implant vendors, paired with its cost-effectiveness, opens accessibility of computer-assisted surgery to all orthopaedic surgeons.

About Intellijoint Surgical Inc.

Intellijoint Surgical is a Waterloo-based innovative medical technology company. Founded in 2010, they develop and commercialize miniaturized surgical smart tools that enhance surgeon accuracy, increase hospital economic efficiencies, and improve patient outcomes. The company’s R&D team is led by the former co-founder of Medtronic’s computer assisted surgery division, and driven by a team of renowned orthopaedic surgeons: Drs. Allan Gross and David Backstein in Toronto, Dr. Wayne Paprosky in Chicago, Dr. Javad Parvizi in Philadelphia and Drs. Michael Cross and Ran Schwarzkopf in New York.

November 5, 2015

AC Grad Intellijoint granted new patents in the US

Intellijoint Surgical’s Patent Portfolio Gains Strength Through the Issuance of New US Patents

AC Graduate Intellijoint Surgical Inc., a medical technology company committed to developing and commercializing low-cost miniaturized surgical smart tools, announced today that the United States Patent and Trademark Office has granted the company a key patent related to its core technology in miniature 3D surgical measurement. The patent, number 9138319, is entitled “Method and system for aligning a prosthesis during surgery”.

Intellectual property development is a strategic cornerstone for Intellijoint Surgical. The company continues to build its patent portfolio through new applications and several recent issuances. The issuances include Intellijoint’s core technology and the surrounding instrumentation enabling it to be placed in a sterile field. Another key patent, entitled “System and method for intra-operative leg position measurement” is expected to issue in early 2016.

“Our miniaturized smart tools are setting the new standard in 3D measurement for surgery,” says Armen Bakirtzian, Chief Executive Officer of Intellijoint Surgical. “Patent issuances are rewarding milestones recognizing the novel technology our organization has created. We will continue to aggressively pursue patents to protect our innovations and build business value”.

Intellijoint graduated from the Accelerator Centre in 2014. The company’s technology provides quantifiable, accurate, intra-operative feedback helping surgeons and hospitals to potentially improve surgical outcomes through accurate implant positioning and selection, ultimately improving patient satisfaction and healthcare economics.

July 15, 2015

The intellijoint HIP is now available across Canada

Intellijoint Surgical Inc., a privately held Canadian medical technology company committed to developing low-cost, miniaturized surgical smart tools, announced today the commercial launch of its flagship product, intellijoint HIP™, for use by orthopaedic surgeons across Canada.

intellijoint HIP is simple, easy to use and provides surgeons with vital intra-operative measurements enabling proper cup position, equalization of leg length and restoration of hip offset. These critical measurements can assist in the prevention of recurrent instability, hip dislocation and leg length discrepancy. intellijoint HIP benefits from the company’s proprietary core technology, a miniaturized surgical grade tracking system placed in the sterile field.

“intellijoint HIP is a revolutionary smart tool that will make a significant impact on patient outcomes in hip replacement surgery and health care system costs worldwide,” said Armen Bakirtzian, Co-Founder and CEO of Intellijoint Surgical. “Use of our device will reduce costly readmissions and unnecessary revision surgeries while improving clinical outcomes and patient satisfaction. We are extremely excited for this milestone and the next steps in our company’s growth.”

The company has successfully conducted a limited launch of intellijoint HIP with 200+ live surgeries in the U.S. and Canada performed by select key opinion leading orthopaedic surgeons. The commercial launch will commence in Ontario, and expand to the rest of the country.

To read more, click here.

February 20, 2014

Accelerator Centre Client Intellijoint Surgical Inc., receives Health Canada Medical Device License for their flagship product, Intellijoint HIP™

Source: Marketwired.com

WATERLOO, ONTARIO–Intellijoint Surgical, Inc. (formerly Avenir Medical) an innovator in smart tools to improve joint replacement surgery, announced today it recently received a Health Canada Medical Device License for its flagship product, Intellijoint HIP™.

The Company also announced early results for its ongoing clinical study with surgeons at Mount Sinai and selected Toronto Area Hospitals showing the Company’s smart tool to be significantly more accurate in determining leg length and offset equivalency than traditional measurement methods used in hip replacement.

Intellijoint’s proprietary device enables surgeons to quantify the key measurements needed for accurate primary and revision hip replacement. “Receiving Health Canada’s license to launch Intellijoint HIP™ in Canada, and our ongoing studies in Toronto Area Hospitals are exciting milestones. ” said Armen Bakirtzian, CEO of Intellijoint.

Read full article here.